Overview

A Study to Measure Baricitinib (LY3009104) Absorption in Healthy Participants

Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare how much baricitinib (study drug) gets into the blood stream when it is given as a single dose (in tablet form) and as an intravenous infusion (injection given directly into a vein via a small needle). Each participant in the study will make four visits to the investigator site over the course of about 6 weeks.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company